163 related articles for article (PubMed ID: 22869563)
1. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.
Al-Saigh R; Elefanti A; Velegraki A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2012 Oct; 56(10):5321-7. PubMed ID: 22869563
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
3. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.
Al-Saigh R; Siopi M; Siafakas N; Velegraki A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2013 Aug; 57(8):3713-8. PubMed ID: 23716054
[TBL] [Abstract][Full Text] [Related]
5. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.
Meletiadis J; Antachopoulos C; Stergiopoulou T; Pournaras S; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3329-37. PubMed ID: 17576838
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
[TBL] [Abstract][Full Text] [Related]
7. A New Marker of Echinocandin Activity in an
Meletiadis J; Siopi M; Tsakris A; Mouton JW; Pournaras S
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463527
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
[TBL] [Abstract][Full Text] [Related]
9. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.
Elefanti A; Mouton JW; Verweij PE; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2014; 58(4):2356-62. PubMed ID: 24514094
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.
Serrano MC; Morilla D; Valverde A; Chávez M; Espinel-Ingroff A; Claro R; Ramírez M; Mazuelos EM
J Clin Microbiol; 2003 Nov; 41(11):5270-2. PubMed ID: 14605181
[TBL] [Abstract][Full Text] [Related]
12. Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated
Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Andes D; Arendrup MC; Mouton JW; Meletiadis J
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229492
[TBL] [Abstract][Full Text] [Related]
13. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp.
Maesaki S; Iwakawa J; Higashiyama Y; Miyazaki Y; Yanagihara K; Tomono K; Tashiro T; Kohno S
J Infect Chemother; 2000 Jun; 6(2):101-3. PubMed ID: 11810544
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
[TBL] [Abstract][Full Text] [Related]
15. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
[TBL] [Abstract][Full Text] [Related]
16. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
17. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of the Orotomides against
Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
[TBL] [Abstract][Full Text] [Related]
19. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.
Espinel-Ingroff A; Rezusta A
J Clin Microbiol; 2002 Jun; 40(6):2101-7. PubMed ID: 12037072
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]